The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Open accessAbstract
BACKGROUND: Drugs that selectively inhibit serotonin reuptake are effective treatments for adults with mood and anxiety disorders, but limited data are available on the safety and efficacy of serotonin-reuptake inhibitors in children with anxiety disorders. METHODS: We studied 128 children who were 6 to 17 years of age; who met the criteria for social phobia, separation anxiety disorder, or generalized anxiety disorder; and who had received psychological treatment for three weeks without improvement. The children were randomly assigned to receive fluvoxamine (at a maximum of 300 mg per day) or placebo for eight weeks and were evaluated with rating scales designed to assess the degree of anxiety and impairment. RESULTS: Children in the fluvoxamine group had a mean (+/-SD) decrease of 9.7+/-6.9 points in symptoms of anxiety on the Pediatric Anxiety Rating Scale (range of possible scores, 0 to 25, with higher scores indicating greater anxiety), as compared with a decrease of 3.1+/-4.8 points among children in the placebo group (P<0.001). On the Clinical Global Impressions-Improvement scale, 48 of 63 children in the fluvoxamine group (76 percent) responded to the treatment, as indicated by a score of less than 4, as compared with 19 of 65 children in the placebo group (29 percent, P<0.001). Five children in the fluvoxamine group (8 percent) discontinued treatment because of adverse events, as compared with one child in the placebo group (2 percent). CONCLUSIONS: Fluvoxamine is an effective treatment for children and adolescents with social phobia, separation anxiety disorder, or generalized anxiety disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Despite its positive effects, the use of paroxetine may have caused as side-effects insomnia, decreased appetite, vomiting, withdrawal, agitation, emotional liability and four patients described suicide ideations without attempting to consummate.”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [41]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, fluvoxamine is considered effective and well tolerated in the long-term treatment of anxiety disorders with children and adolescents [40].”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the fluvoxamine condition drop-out was higher (n = 5) than the placebo group (n = 2) due to sideeffects.”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, studies examining the efficacy of fluvoxamine and sertraline have reported a significant reduction in the severity of the anxiety symptoms after only 12 weeks [37,59].”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additional research suggests that combining psychotherapy with pharmacotherapy yields better outcomes than either approach alone, as psychotherapy can teach valuable skills in managing fear-inducing social situations while pharmacotherapy alleviates symptoms facilitating greater participation in behavioral interventions [60,61].”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [60]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Another study found that 76% of participants treated with fluvoxamine were classified as 'much improved,' compared to 29% in the placebo group [59].”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [59]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The participants allocated to the fluvoxamine experimental group benefited from a significant decrease in anxiety symptoms compared to the participants allocated to the placebo group.”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“The most prevalent observed side-effects were headache, abdominal discomfort, increased motor activity and difficulty falling asleep.”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148
A Children's Global Assessment Scale (CGAS)
Shaffer, D. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790100074010 · Cited by 3,716
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
BIRMAHER, B., KHETARPAL, S., BRENT, D., CULLY, M., BALACH, L., KAUFMAN, J., & NEER, S. M. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199704000-00018 · Cited by 2,846
The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity
MARCH, J. S., PARKER, J. D. A., SULLIVAN, K., STALLINGS, P., & CONNERS, C. K. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199704000-00019 · Cited by 2,236
Self-citationPine, D. S., Cohen, P., Gurley, D., Brook, J., & Ma, Y. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.1.56 · Cited by 1,753
Self-citationSHAFFER, D., FISHER, P., DULCAN, M. K., DAVIES, M., PIACENTINI, J., SCHWAB-STONE, M. E., LAHEY, B. B., BOURDON, K., JENSEN, P. S., BIRD, H. R., et al. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199607000-00012 · Cited by 1,587
Self-citationUsers' Guides to the Medical Literature
Guyatt, G. H. (1993) · JAMA · doi:10.1001/jama.270.21.2598 · Cited by 1,185
Emslie, G. J. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230069010 · Cited by 971
Research works printed but not linked: 3
- Greenhill LL, 1998, Psychopharmacol Bull, 34, 155
- Walkup J, Davies M. The Pediatric Anxiety Rating Scale (PARS): a reliability study. In: Scientific proceedings of the 46th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Chicago, October 19–24, 1999:NR78. abstract.
- Wagner KD, Birmaher B, Carlson G, et al. Multi-center trial of paroxetine and imipramine in the treatment of adolescent depression. In: Scientific proceedings of the 45th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Anaheim, Calif., October 27–November 1, 1998:S12D. abstract.
Cited by
Sorted by citations
Items 301–400 of 589
A Review of Preclinical Studies to Understand Fear During Adolescence
Kim, J. H., & Ganella, D. E. (2015) · Australian Psychologist · doi:10.1111/ap.12066 · Cited by 20
Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders
Altamura, A. C., Caldiroli, A., & Buoli, M. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1021331 · Cited by 20
Johnco, C. J., Salloum, A., Lewin, A. B., & Storch, E. A. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0102 · Cited by 20
Albano, A. M., Comer, J. S., Compton, S. N., Piacentini, J. C., Kendall, P. C., Birmaher, B. B., Walkup, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J. T., et al. (2017) · Evidence-Based Practice in Child and Adolescent Mental Health · doi:10.1080/23794925.2017.1399485 · Cited by 20
Self-citationThe pharmacological treatment of childhood anxiety disorders
Walkup, J. T., Labellarte, M. J., & Ginsburg, G. S. (2002) · International Review of Psychiatry · doi:10.1080/09540260220132653 · Cited by 20
Self-citationThe New Medical Model: Interdisciplinary Treatment and the Limits of Behaviorism
Forness, S. R., Kavale, K. A., & Davanzo, P. A. (2002) · Behavioral Disorders · doi:10.1177/019874290202700203 · Cited by 20
Drug Treatment of Anxiety Disorders in Children
COYLE, J. T. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441711 · Cited by 20
Stefánsdóttir, Í. H., Ivarsson, T., & Skarphedinsson, G. (2023) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2022.2075460 · Cited by 19
Reliability and validity of the Pediatric Anxiety Rating Scale modified for autism spectrum disorder
Maddox, B. B., Lecavalier, L., Miller, J. S., Pritchett, J., Hollway, J. A., White, S. W., Gillespie, S. E., Evans, A. N., Schultz, R. T., Herrington, J. D., et al. (2020) · Autism · doi:10.1177/1362361320922682 · Cited by 21
Pharmacologic Treatment of Pediatric Anxiety Disorders
Hussain, F. S., Dobson, E. T., & Strawn, J. R. (2016) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-016-0076-7 · Cited by 20
A computational network perspective on pediatric anxiety symptoms
Abend, R., Bajaj, M. A., Coppersmith, D. D. L., Kircanski, K., Haller, S. P., Cardinale, E. M., Salum, G. A., Wiers, R. W. H. J., Salemink, E., Pettit, J. W., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720000501 · Cited by 21
Self-citationBrooks, S. J., & Kutcher, S. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041649002 · Cited by 20
Pary, R., Matuschka, P. R., Lewis, S., Caso, W., & Lippmann, S. (2003) · Southern Medical Journal · doi:10.1097/01.smj.0000054499.21994.a5 · Cited by 20
Translation of Anxiety Treatment to Youth with Autism Spectrum Disorders
Selles, R. R., & Storch, E. A. (2012) · Journal of Child and Family Studies · doi:10.1007/s10826-012-9593-1 · Cited by 20
Purper‐Ouakil, D., Cohen, D., & Flament, M. F. (2011) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2011.03.001 · Cited by 20
Mediators of Treatment Outcomes for Anxious Children and Adolescents: The Role of Somatic Symptoms
Hale, A. E., Ginsburg, G. S., Chan, G., Kendall, P. C., McCracken, J. T., Sakolsky, D. J., Birmaher, B. B., Compton, S. N., Albano, A. M., & Walkup, J. T. (2017) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2017.1280804 · Cited by 18
Self-citationDumortier, G., Welniarz, B., Sauvebois, C., Medjdoub, H., Friche, H., Siad, N., & Degrassat, K. (2005) · L Encéphale · doi:10.1016/s0013-7006(05)82409-1 · Cited by 18
PHARMACOTHERAPY OF SOCIAL ANXIETY DISORDER AT THE TURN OF THE MILLENNIUM
Ameringen, M. V., & Mancini, C. (2001) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70263-x · Cited by 18
Psychopharmacology Interventions for Pediatric Anxiety Disorders: A Research Update
Waslick, B. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.009 · Cited by 17
Escitalopram Treatment in Preschool Children with Anxiety Disorders: A Case Series
Coşkun, M., Öztürk, M., & Zoroglu, S. S. (2012) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20120729101822 · Cited by 16
The Feasibility and Effectiveness of School-Based Modular Therapy: A Systematic Literature Review
Kininger, R. L., O’Dell, S. M., & Schultz, B. K. (2018) · School Mental Health · doi:10.1007/s12310-018-9270-7 · Cited by 17
Benefits and risks of using antidepressants in children and adolescents
Bailly, D. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.1.9 · Cited by 17
Russo‐Ponsaran, N. M., Yesensky, J. A., Hessl, D. R., & Berry‐Kravis, E. (2014) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-119.1.1 · Cited by 18
“…Ginsburg, Palapattu, & Walkup, 2004; Riddle et al., 2002) was identified as a potentially useful tool based on its face validity for FXS and its sensitivity in prior controlled pharmacological trials in pediatric anxiety disorders (Birmaher et al., 2003; Geller et al., 2007; Walkup et al., 2001).”
BackgroundMethodReasons for Hope for Children and Families: A Perspective and Overview
Burns, B. J. (2002) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195134575.003.0001 · Cited by 17
Emerging Domain-Based Treatments for Pediatric Anxiety Disorders
Lazarov, A., & Bar‐Haim, Y. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.08.030 · Cited by 17
Lehman, R. B. (2002) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0216 · Cited by 17
Pharmacotherapy of childhood anxiety disorders
Kratochvil, C. J., Harrington, M. J., Burke, W. J., & March, J. S. (2002) · Current Psychiatry Reports · doi:10.1007/s11920-996-0045-8 · Cited by 17
Self-citationGothelf, D., & Cohen, I. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm200407153510322 · Cited by 17
Advances in Pharmacotherapy for Pediatric Anxiety Disorders
Nicotra, C. M., & Strawn, J. R. (2023) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2023.02.006 · Cited by 16
Cheer, S. M., & Figgitt, D. P. (2001) · Paediatric Drugs · doi:10.2165/00128072-200103100-00004 · Cited by 15
Pragmatic measures in paediatric psychopharmacology — Are we getting it right?
Coghill, D. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.11.007 · Cited by 16
Dobson, E. T., & Strawn, J. R. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0153-1 · Cited by 16
Korczak, D. J., & Canadian Paediatric Society (2013) · Paediatrics & Child Health · doi:10.1093/pch/18.9.487 · Cited by 16
Anxiety in the Pediatric Medical Setting
Gandhi, B., Cheek, S., & Campo, J. V. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.05.013 · Cited by 16
Antidepressant‐Induced Manic Conversion: A Developmentally Informed Synthesis of the Literature
Lim, C. J., Leckman, J. F., Young, C., & Martin, A. (2005) · International review of neurobiology · doi:10.1016/s0074-7742(04)65002-1 · Cited by 16
Pharmacotherapy for Anxiety Disorders in Children and Adolescents: An Evidence-Based Medicine Review
Compton, S. N., Kratochvil, C. J., & March, J. S. (2007) · Pediatric Annals · doi:10.3928/0090-4481-20070901-10 · Cited by 16
Self-citationPsychopharmacology in the schools
Abrams, L. M., Flood, J., & Phelps, L. (2006) · Psychology in the Schools · doi:10.1002/pits.20163 · Cited by 16
Evidence-based psychopharmacology for children and adolescents
Coghill, D. (2002) · Current Opinion in Psychiatry · doi:10.1097/00001504-200207000-00004 · Cited by 16
Child psychiatry: A scientometric analysis 1980-2016
Naveed, S., Waqas, A., Majeed, S., Zeshan, M., Jahan, N., & Sheikh, M. H. (2017) · F1000Research · doi:10.12688/f1000research.12069.1 · Cited by 14
Cognitive-Behavior Therapy for Childhood Anxiety Disorders
Roblek, T., & Piacentini, J. C. (2005) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.06.001 · Cited by 15
Self-citationHarris, E., Eng, H. Y., Kowatch, R. A., Delgado, S. V., & Saldaña, S. N. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0126 · Cited by 15
Pediatric Social Anxiety Disorder: Predictors of Response to Pharmacological Treatment
Masi, G., Pfanner, C., Mucci, M., Berloffa, S., Magazù, A., Parolin, G., & Perugi, G. (2012) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0007 · Cited by 16
Salloum, A., Scheeringa, M. S., Cohen, J. A., & Storch, E. A. (2014) · Child & Youth Care Forum · doi:10.1007/s10566-014-9270-1 · Cited by 14
Günther, T., Holtkamp, K., JOLLES, J., Herpertz‐Dahlmann, B., & Konrad, K. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.608 · Cited by 14
Psychostimulants in Attention Deficit Hyperactivity Disorder
Connor, D. F. (2005) · Contemporary clinical neuroscience · doi:10.1385/1-59259-891-9:487 · Cited by 15
Mueller, S. C., Shechner, T., Rosen, D. K., Nelson, E. E., Pine, D. S., & Ernst, M. (2015) · Depression and Anxiety · doi:10.1002/da.22350 · Cited by 14
Self-citationApproaches to Multisite Clinical Trials: The National Institute of Mental Health Perspective
Lebowitz, B. D., Vitiello, B., & NORQUIST, G. S. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006992 · Cited by 14
Self-citationChildhood anxiety disorders and developmental issues in anxiety
Arnold, P. D., Banerjee, S. P., Bhandari, R. P., Ivey, J., Rose, M., & Rosenberg, D. R. (2003) · Current Psychiatry Reports · doi:10.1007/s11920-003-0054-9 · Cited by 15
Liebowitz, M. R., Ninan, P. T., Schneier, F. R., Blanco, C., Ginsberg, D. L., & Hollander, E. (2005) · CNS Spectrums · doi:10.1017/s1092852900028066 · Cited by 14
Anxiety Regulation: A Developmental Psychopathology Perspective
Tone, E. B., Garn, C. L., & Pine, D. S. (2016) · Wiley eBooks · doi:10.1002/9781119125556.devpsy214 · Cited by 14
Self-citationAPA Working Group on Psychoactive Medications for Children and Adolescents (2006) · PsycEXTRA Dataset · doi:10.1037/e539722009-001 · Cited by 14
Heterogeneity in Major Depressive Disorder: Lessons From Developmental Research on Irritability
Pine, D. S. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020214 · Cited by 14
Self-citationSimonoff, E. A., Mowlem, F. D., Pearson, O., Anagnostou, E. A., Donnelly, C. L., Hollander, E., King, B. H., McCracken, J. T., Scahill, L. D., Sikich, L., et al. (2022) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2021.0137 · Cited by 16
“…phobia, and separation anxiety disorder, but not obsessive-compulsive disorder or posttraumatic stress disorder, in line with the inclusion of disorders in pharmacological studies in typically developing anxious children (Research Units on Pediatric Psychopharmacology 2001; Walkup et al. 2008).”
Self-citationMittal, M., Harrison, D. L., Miller, M. J., & Brahm, N. C. (2013) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2013.11.001 · Cited by 13
Cochrane Review: Pharmacotherapy for anxiety disorders in children and adolescents
Ipser, J., Stein, D. J., Hawkridge, S. M., & Hoppe, L. J. (2010) · Evidence-Based Child Health A Cochrane Review Journal · doi:10.1002/ebch.541 · Cited by 13
Strawn, J. R., Poweleit, E. A., Mills, J. A., Schroeder, H. K., Neptune, Z. A., Specht, A. M., Farrow, J. E., Zhang, X., Martin, L. J., & Ramsey, L. B. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111188 · Cited by 15
Psychosocial and pharmacological treatment for pediatric anxiety disorders
Fisher, P. H., Tobkes, J. L., Kotcher, L. B., & Masia‐Warner, C. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.11.1707 · Cited by 14
An Update on Publicly Funded Multisite Trials in Pediatric Psychopharmacology
Vitiello, B. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.010 · Cited by 13
Self-citationBailly, D. (2006) · La Presse Médicale · doi:10.1016/s0755-4982(06)74808-4 · Cited by 13
Understanding and Treating Social Phobia
Curtis, R. C., Kimball, A., & Stroup, E. L. (2004) · Journal of Counseling & Development · doi:10.1002/j.1556-6678.2004.tb00279.x · Cited by 12
McClure, E. B., & Pine, D. S. (2015) · Wiley eBooks · doi:10.1002/9780470939406.ch12 · Cited by 13
Self-citationPharmacotherapy for Children and Adolescents with Anxiety Disorders
Vitiello, B., & WASLICK, B. D. (2010) · Psychiatric Annals · doi:10.3928/00485713-20100330-09 · Cited by 12
Self-citationAngststörungen und Phobien im Kindes- und Jugendalter
Schneider, S., & In‐Albon, T. (2010) · Psychotherapeut · doi:10.1007/s00278-010-0724-0 · Cited by 14
Pharmacological treatment options for panic disorder in children and adolescents
Masi, G., Pari, C., & Millepiedi, S. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.5.545 · Cited by 12
Stein, D. J. (2013) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v19i3.950 · Cited by 13
Social Stress, Affect, and Neural Function in Adolescence
McClure, E. B., & Pine, D. S. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195306255.003.0010 · Cited by 12
Self-citationParoxetine in the treatment of generalised anxiety disorder
Snyderman, S. H., Rynn, M. A., Bellew, K. M., & Rickels, K. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.8.1799 · Cited by 12
Pediatric Psychopharmacology for Prepubertal Internalizing Disorders.
Kubiszyn, T. W., Carlson, J. S., & DeHay, T. L. (2005) · School Psychology Quarterly · doi:10.1521/scpq.20.2.135.66513 · Cited by 12
Special Education: Best Practices and First Step to Success
Epstein, M. H., & Walker, H. M. (2002) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195134575.003.0009 · Cited by 13
Bailly, D. (2006) · La Presse Médicale · doi:10.1016/s0755-4982(06)74843-6 · Cited by 12
Piacentini, J. (2002) · Western Journal of Medicine · doi:10.1136/ewjm.176.3.149 · Cited by 11
Self-citationCoghill, D. (2003) · Advances in Psychiatric Treatment · doi:10.1192/apt.9.4.289 · Cited by 11
The best next drug in the course of generalized anxiety disorders: the “PN-GAD-algorithm”
Linden, M., Bandelow, B., Boerner, R. J., Brasser, M., Kasper, S. F., Möller, H., Pyrkosch, L., Volz, H., & Wïttchen, H. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.722645 · Cited by 11
Recent developments and strategies in pediatric pharmacology research in the USA
Vitiello, B. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-36 · Cited by 11
Self-citationAnxiety disorders in children and adolescents
Vallance, A. K., & Garralda, M. E. (2008) · Psychiatry · doi:10.1016/j.mppsy.2008.05.014 · Cited by 11
Polysaccharide Conjugate Typhoid Vaccine
Guerrant, R. L., & Kosek, M. N. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441709 · Cited by 11
Current and Future Approaches to Pediatric Anxiety Disorder Treatment
Zugman, A., Winkler, A. M., Qamar, P., & Pine, D. S. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20231037 · Cited by 16
Self-citationPires, G. C., Rockett, F. C., Salum, G. A., Manfro, G. G., & Bosa, V. L. (2005) · PubMed · doi:10.3305/nh.2015.31.1.7523 · Cited by 12
“These findings are in agreement with those of Pine et al. (2001)26.”
ResultCombining and sequencing medication and cognitive-behaviour therapy for childhood anxiety disorders
Keeton, C. P., & Ginsburg, G. S. (2008) · International Review of Psychiatry · doi:10.1080/09540260801889047 · Cited by 10
Psychopharmacologic Treatment for Pediatric Anxiety Disorders
Peters, T. E., & Connolly, S. D. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.007 · Cited by 11
Autistic spectrum disorders: Diagnostic and therapeutic challenges in Mexico
Márquez-Caraveo, M. E., & Albores‐Gallo, L. (2011) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 10
Developmental Changes in the Association Between Cognitive Control and Anxiety
Filippi, C. A., Subar, A. R., Ravi, S., Haas, S., Troller‐Renfree, S. V., Fox, N. A., Leibenluft, E., & Pine, D. S. (2021) · Child Psychiatry & Human Development · doi:10.1007/s10578-021-01150-5 · Cited by 10
Self-citationPalitz, S. A., & Kendall, P. C. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-30687-8_7 · Cited by 11
Arnardóttir, A., & Skarphedinsson, G. (2023) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2022.2069858 · Cited by 9
“Medication is also associated with adverse events [10,14,24].”
BackgroundStevens, E. S., Jendrusina, A. A., Sarapas, C., & Behar, E. (2014) · The Wiley Handbook of Anxiety Disorders · doi:10.1002/9781118775349.ch21 · Cited by 9
Haller, S. P., Stoddard, J., MacGillivray, C., Stiles, K., Perhamus, G. R., Penton‐Voak, I. S., Bar‐Haim, Y., Munafo, M. R., & Brotman, M. A. (2018) · Trials · doi:10.1186/s13063-018-2960-5 · Cited by 10
Aggarwal, N., Tromp, D., Blackford, J. U., Pine, D. S., Roseboom, P. H., Williams, L. E., & Kalin, N. H. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20221048 · Cited by 9
Self-citationThe role of pharmacotherapy in the management of self-regulation difficulties in young children.
Reebye, P. N., & Elbe, D. (2009) · Europe PMC (PubMed Central) · Cited by 9
Outpatient treatment of children and adolescents with antidepressants in Croatia
Maršanić, V. B., Margetić, B. A., & Margetić, B. (2011) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2011.640939 · Cited by 9
Assessing and Treating Social Phobia in Children and Adolescents
Ginsburg, G. S., & Grover, R. L. (2005) · Pediatric Annals · doi:10.3928/0090-4481-20050201-10 · Cited by 9
Jurbergs, N., & Ledley, D. R. (2005) · Psychiatric Annals · doi:10.3928/00485713-20050901-05 · Cited by 9
Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY) Part II
Pappadopulos, E. A., MacIntyre, J. C., Crismon, M. L., Findling, R. L., Malone, R. P., Derivan, A., Schooler, N. R., Sikich, L., Greenhill, L. L., Schur, S. B., et al. (2004) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.2.4.608 · Cited by 9
Self-citationAnxiolytics and Sedative-Hypnotics
Gerlach, M., & Warnke, A. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1501-5_6 · Cited by 9
Pharmacological Treatment of Anxiety Disorders in Children and Adolescents
Birmaher, B. B., & Sakolsky, D. J. (2012) · Wiley eBooks · doi:10.1002/9781118315088.ch11 · Cited by 9
Accounting for center-level effects in multicenter randomized controlled trials
Islam, S., & Bangdiwala, S. I. (2024) · Trials · doi:10.1186/s13063-024-08202-w · Cited by 10
Beidel, D. C., Le, T.-A. P., & Willis, E. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813004-9.00010-4 · Cited by 10
Blindness of Clinical Evaluators, Parents, and Children in a Placebo-Controlled Trial of Fluvoxamine
Vitiello, B., Davis, M. D. P., Greenhill, L. L., & Pine, D. S. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.219 · Cited by 8
Self-citationMaia, C. R. M., & Rohde, L. A. (2006) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462006005000019 · Cited by 8
Psychopharmacology for Medically Ill Adolescents
Bursch, B., & Forgey, M. J. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0395-y · Cited by 8
Karpouzis, F., Pollard, H. P., & Bonello, R. (2008) · Journal of Chiropractic Medicine · doi:10.1016/j.jcm.2008.05.003 · Cited by 8
Metadata
- Authors
- Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., Klee, B., McCracken, J., Bergman, L., Piacentini, J., March, J., Compton, S., Robinson, J., O'Hara, T., Baker, S., Vitiello, B., Ritz, L., & Roper, M.
- Affiliations
- New York State Psychiatric Institute (US)
- University of California, Los Angeles (US)
- Duke University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-04-26
- Volume
- 344
- Issue
- 17
- Pages
- 1279-1285
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2330595721
- Cited by
- 588
- References
- 42
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 18 · 2023: 7 · 2022: 12 · 2021: 14 · 2020: 12 · 2019: 15 · 2018: 10 · 2017: 18 · 2016: 17 · 2015: 19 · 2014: 20 · 2013: 23 · 2012: 23
- FWCI
- 73.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Brown University
- Johns Hopkins University
- York University
- National Institutes of Health (n01mh060005-010, n01mh060016-007, n01mh070010-001)
- University of Illinois at Urbana-Champaign
- National Institute of Mental Health (N01 MH 70010, N01 MH60005, N01MH60016)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- fluvoxamine, selective serotonin reuptake inhibitors, childhood anxiety disorders, social anxiety disorder, separation anxiety disorder, generalized anxiety disorder, children and adolescents, drug safety and efficacy, adverse events
- MeSH terms
- Adolescent, Anxiety Disorders, Anxiety, Separation, Child, Female, Humans, Male, Phobic Disorders, Psychotherapy, Anti-Anxiety Agents, Fluvoxamine, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
